Another demonized "party drug" is getting a new looksie, as its potential as a medicine is explored:

MDMA's partial rehabilitation is largely due to the efforts of Rick Doblin and his Multidisciplinary Association for Psychedelic Studies. MAPS has raised the money for the Mithoefer trial and other studies aimed at testing the medical or psychotherapeutic value of currently banned substances, and it has led the way through the bureaucratic maze that must be traversed to obtain legal approval for such research. Its ultimate goal is to make Schedule I substances such as MDMA, LSD, ibogaine, and marijuana available by prescription.

But some sick people could get better! MDMA, of course, began life as a medical psychiatric therapy. It was only when it gave people pleasure and helped them think through and resolve their emotional problems that the government decided to ban it.

We want to hear what you think about this article. Submit a letter to the editor or write to letters@theatlantic.com.